Related Experiment Video
Updated: Feb 10, 2026

Electric Cell-substrate Impedance Sensing for the Quantification of Endothelial Proliferation, Barrier Function, and Motility
Published on: March 28, 2014
Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant
D M Tiek1, J D Rone2, G T Graham2
1Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. dmt53@georgetown.edu.
Abstract:
Glioblastoma (GBM) is an aggressive and incurable tumor of the brain with limited treatment options. Current first-line standard of care is the DNA alkylating agent temozolomide (TMZ), but this treatment strategy adds only ~4 months to median survival due to the rapid development of resistance. While some mechanisms of TMZ resistance have been identified, they are not fully understood. There are few effective strategies to manage therapy resistant GBM, and we lack diverse preclinical models of acquired TMZ resistance in which to test therapeutic strategies on TMZ resistant GBM. In this study, we create and characterize two new GBM cell lines resistant to TMZ in vitro, based on the 8MGBA and 42MGBA cell lines. Analysis of the TMZ resistant (TMZres) variants in conjunction with their parental, sensitive cell lines shows that acquisition of TMZ resistance is accompanied by broad phenotypic changes, including increased proliferation, migration, chromosomal aberrations, and secretion of cytosolic lipids. Importantly, each TMZ resistant model captures a different facet of the "go" (8MGBA-TMZres) or "grow" (42MGBA-TMZres) hypothesis of GBM behavior. These in vitro model systems will be important additions to the available tools for investigators seeking to define molecular mechanisms of acquired TMZ resistance.
Insights
Researchers developed new glioblastoma (GBM) cell lines resistant to temozolomide (TMZ). These models exhibit phenotypic changes and will aid in understanding and treating therapy-resistant GBM.
Area of Science:
- Neuro-oncology
- Cancer biology
- Drug resistance mechanisms
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
- Temozolomide (TMZ) is the standard first-line therapy, but resistance significantly limits its efficacy.
- There is a critical need for preclinical models to study acquired TMZ resistance in GBM.
Purpose of the Study:
- To create and characterize novel in vitro glioblastoma cell lines with acquired resistance to temozolomide (TMZ).
- To investigate the phenotypic and molecular changes associated with TMZ resistance.
- To provide new tools for studying therapy-resistant GBM.
Main Methods:
- Development of two new TMZ-resistant GBM cell lines (TMZres) from parental 8MGBA and 42MGBA lines.
- Comparative analysis of TMZ-resistant variants and their sensitive parental lines.
- Characterization of phenotypic changes including proliferation, migration, chromosomal aberrations, and lipid secretion.
Main Results:
- Successful generation of two distinct TMZ-resistant GBM cell line models.
- Acquisition of TMZ resistance was associated with significant phenotypic alterations.
- The models reflect different aspects of the "go" or "grow" hypotheses of GBM behavior.
Conclusions:
- The newly developed TMZ-resistant GBM cell lines are valuable preclinical tools.
- These models will facilitate research into the molecular mechanisms of acquired TMZ resistance.
- Understanding these mechanisms is crucial for developing effective strategies against therapy-resistant GBM.
Related Concept Videos
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Microtubules in Cell Motility
Cells Coordinate Growth and Proliferation
What is Metabolism?
Actin Polymerization and Cell Motility
Actin cytoskeleton dynamics can produce pushing, pulling, and resistance forces that help the cell to migrate....
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...

